Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Other

Harnessing blue light photobiomodulation for cancer therapy: Evidence from a systematic review

Despite the encouraging findings, considerable methodological heterogeneity and insufficient reporting of dosimetric parameters compromise the reproducibility and comparability of results across studies.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

This qualitative systematic review analyzed 37 in vitro and in vivo studies of blue light (450-470 nm) in pre-clinical cancer models. The authors report that blue light reduced cell viability, proliferation, migration and invasion, increased reactive oxygen species and induced apoptosis, and that in animal models it inhibited tumor growth and metastasis. The authors note that the evidence is limited by methodological heterogeneity and incomplete reporting of dosimetry.

Studies included
37
Who or what was studied
Pre-clinical cancer models (in vitro cell studies and in vivo animal studies)
Wavelengths
450, 470 nm
Limits stated in the abstract
The abstract notes considerable methodological heterogeneity and insufficient reporting of dosimetric parameters, which compromise reproducibility and comparability across studies.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Cancer is a chronic disease responsible for millions of deaths annually. Its multifaceted profile, with diverse types and anatomical locations, complicates treatment, often limited to surgery, radiotherapy, and chemotherapy. These treatments are frequently associated with increased tumor aggressiveness and recurrence, highlighting the urgent need for new, less invasive therapies. Recent studies suggest that blue light (BL; 450-470 nm) may offer anti-tumor and pro-apoptotic effects, making it a promising alternative for cancer treatment. However, its cellular and molecular mechanisms remain unclear. This qualitative systematic review, conducted in accordance with PRISMA guidelines, analyzed 37 in vitro and in vivo studies published between 2002 and 2024, retrieved from databases including MEDLINE/PubMed, EMBASE, and LILACS, with a focus on the effects of photobiomodulation (PBM) with blue light (450-470 nm) in pre-clinical cancer models. BL demonstrated anti-tumor potential by reducing cell viability, proliferation, migration, and invasion, as well as increasing ROS production and inducing apoptosis. In animal models, BL also inhibited tumor growth, metastasis, and improved survival. Despite the encouraging findings, considerable methodological heterogeneity and insufficient reporting of dosimetric parameters compromise the reproducibility and comparability of results across studies. These findings underscore the therapeutic potential of BL in oncology and highlight the need for standardized protocols to support clinical translation.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

Light parameters mentioned

Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.

Wavelength
450-470 nm

How to read a review: what to check before relying on this kind of research.

Terms in this paper: Photobiomodulation, Systematic review, Reactive oxygen species, Heterogeneity. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies

Other

Effect of 460 nm blue light PBM on human MeWo melanoma cells

Although the cells initially attempt to resist the stress induced by the treatment, they eventually undergo apoptosis over time. These findings contribute to understanding melanoma's molecular response to blue light PBM, lay the groundwork for future clinical applications.

Study · June 27, 2024 · Qin H et al.